Absci is a drug and target discovery company. Co. develops an integrated drug creation platform by merging deep learning artificial intelligence (AI) and synthetic biology. The integrated drug creation platform enables target identification, and parallel discovery of biologics and with production cell lines by incorporating biodiversity, high-throughput single cell single cell assays, and deep learning AI models. Co. uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and Co. learns from the data it generates. Co.'s designs are AI-informed and its technology platform is scaffold-agnostic. The ABSI average annual return since 2021 is shown above.
The Average Annual Return on the ABSI average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ABSI average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ABSI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|